BioPhausia becomes Apoteksgruppen's main supplier of parallel-imported pharmaceuticals

BioPhausia has signed a long-term supply agreement with Apoteksgruppen, one of
Sweden's largest pharmacy chains. Under the agreement, BioPhausia will become
Apoteksgruppen's main supplier of parallel-imported pharmaceuticals through the
Company's subsidiary Cross Pharma.

BioPhausia has also signed a supply agreement with another large pharmacy chain.
"We are delighted to have concluded this important agreement with one of
Sweden's leading pharmacy chains," says BioPhausia's CEO Claes Thulin. "Our
partnership with Apoteksgruppen is evidence that the re-regulation of the
Swedish pharmacy market is creating new business opportunities for companies
like us."The agreement with Apoteksgruppen covers continuous delivery of 100
parallel-imported pharmaceuticals for various indications, including the
cardiovascular system, stomach and intestines, asthma and the central nervous
system. All parallel-imported products are originator drugs with patent
protection.

Parallel import represents an important business segment for BioPhausia, which
is currently Sweden's fourth largest parallel import company. These operations
are run in the wholly-owned subsidiary Cross Pharma, which reported annual sales
of SEK 297 million in 2009. Cross Pharma is constantly renewing and broadening
its product portfolio and the aim is to expand further into existing and new
markets. Cross Pharma's parallel trade contributes towards sharpening the
Company's competitiveness and placing price pressure on prescription drugs with
patent protection.

Apoteksgruppen is one of the new pharmacy chains created when the Swedish
pharmacy market was re-regulated. The group's sales for 2009 amounted to SEK
3.9 billion, which corresponds to a market share of 13 percent. The chain has
150 pharmacies - from Gällivare in the north to Borrby in the south - run by
local small entrepreneurs under a common service organisation. Apoteksgruppen is
the fourth largest chain in Sweden.

For further information, please contact:

Claes Thulin, CEO +46 8 407 64 30



[HUG#1413203]